209 related articles for article (PubMed ID: 12973652)
1. EU launches measures to stop diversion of cut-price drugs.
Fleck F
Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
[No Abstract] [Full Text] [Related]
2. Drug companies should cut prices for developing countries, says G8 report.
Walgate R
Bull World Health Organ; 2003; 81(1):72-3. PubMed ID: 12640481
[No Abstract] [Full Text] [Related]
3. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
4. Reprivatizing pharmaceutical supplies in Africa.
Turshen M
J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
[TBL] [Abstract][Full Text] [Related]
5. The Affordable Prescription Drugs Act: a solution for today's high prescription drug prices.
Pinzone JD
J Law Health; 2001-2002; 16(1):145-68. PubMed ID: 14650775
[No Abstract] [Full Text] [Related]
6. No deal in sight on cheap drugs for poor countries.
Fleck F
Bull World Health Organ; 2003; 81(4):307-8. PubMed ID: 12764500
[No Abstract] [Full Text] [Related]
7. Access to critical medicines: When are compulsory licenses effective in price negotiations?
Ramani SV; Urias E
Soc Sci Med; 2015 Jun; 135():75-83. PubMed ID: 25957163
[TBL] [Abstract][Full Text] [Related]
8. Access to and price of medicines globally.
Myhr K
Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2019-21. PubMed ID: 22016132
[No Abstract] [Full Text] [Related]
9. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
10. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
11. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
12. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
13. [Access of developing countries to essential drugs: a process of equity].
Campion MD
Bull Acad Natl Med; 2001; 185(7):1255-66; discussion 1266-9. PubMed ID: 11975322
[TBL] [Abstract][Full Text] [Related]
14. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
15. Access to essential drugs prevented by pharmaceutical multinationals.
Dev World Bioeth; 2001 May; 1(1):1-6. PubMed ID: 12870503
[No Abstract] [Full Text] [Related]
16. Innovation and the WHO's essential medicines list: giving credit where credit is due.
Wertheimer AI; Santella TM
Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
[No Abstract] [Full Text] [Related]
17. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
Sonderholm J
J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
[TBL] [Abstract][Full Text] [Related]
18. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
19. Philippines joins other developing countries in limiting prices of drugs.
Bland B
BMJ; 2009 Aug; 339():b3151. PubMed ID: 19651688
[No Abstract] [Full Text] [Related]
20. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
